Роль трипторелина (Диферелин) в лечении рака предстательной железы

1. Аксель Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России в 2003 г. Онкоурология 2005;(1):6—9.

2. Minkov N.K., Zozikov B.I., Yaneva Z., Uldry P.A. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. Int Urol Nephrol 2001;33(2):379—83.

3. Bouchot O., Soret J.Y., Jacqmin D. et al. Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. Horm Res 1998;50(2):89—93.

4. Klippel K.F., Winkler C.J., Jocham D. et al. Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma. Urologe A 1999;38(3):270—5.

5. Gonzalez-Barcena D., Perez-Sanchez P.L., Graef A. et al. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma. Prostate 1989;14(4):291—300.

6. Labrie F., Dupont A., Belanger A. et al. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br Med J (Clin Res Ed) 1985 10;291(6492):369—70.

7. Seppelt U., Bertermann H., Saerbeck C. Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation. Urologe A 1986;25(5):298—301.

8. Boccardo F., Decensi A., Guarneri D. et al. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study. Prostate 1987;11(3):243—55.

9. Roger M., Duchier J., Lahlou N., Schally A.V. Treatment of prostatic cancers by periodic administration of a delayedrelease preparation of D-Trp(6)-LHRH. Ann Urol (Paris) 1986;20(2):109—12.

10. Dupont A., Cusan L., Gomez J.L. et al. Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. Br J Urol 1993;72(5 Pt 1):629—34.

11. Steg A., Chiche R., Boccon-Gibod L., Debre B. Treatment of advanced prostatic cancer with a gonadorelin agonist, D-Trp6-LHRH. 41 cases. Presse Med 1985;14(40):2045—8.

12. Gonzalez-Barcena D., Perez-Sanchez P., Ureta-Sanchez S. et al. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH. Prostate 1985;7(1):21—30.

13. Mathe G., Misset J.L., Vovan M.L., Machover D. Advanced cancer of the prostate. Treatment with an LH-RH agonist, D-Trp-6-LH-RH. Bull Cancer 1986;73(1):31—5.

14. Parmar H., Edwards L., Phillips R.H. et al. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1987;59(3):248—54.

15. Mathe G., Schally A.V., Comaru-Schally A.M. et al. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents. Prostate 1986;9(4):327—42.

16. Maillefert J.F., Sibilia J., Michel F. et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161(4):1219—22.